Centocor's Remicade on hold for CHF

Johnson & Johnson (JNJ) subsidiary Centocor (Malvern, Penn.) said that a Phase II trial of its Remicade infliximab to treat advanced congestive heart failure (CHF) has been placed on hold. A preliminary data review showed no improvement in patients' clinical status and a higher incidence of mortality and hospitalization for worsening heart failure in the Remicade group, especially at the higher dose of 10 mg/kg, Centocor said. ...